2023
Clinical Phenotypes of Patients With Systemic Sclerosis With Distinct Molecular Signatures in Skin
Yang M, Goh V, Lee J, Espinoza M, Yuan Y, Carns M, Aren K, Chung L, Khanna D, McMahan ZH, Agrawal R, Nelson L, Shah SJ, Whitfield ML, Hinchcliff M. Clinical Phenotypes of Patients With Systemic Sclerosis With Distinct Molecular Signatures in Skin. Arthritis Care & Research 2023, 75: 1469-1480. PMID: 35997480, PMCID: PMC9947190, DOI: 10.1002/acr.24998.Peer-Reviewed Original ResearchConceptsRadiographic interstitial lung diseaseInterstitial lung diseaseHigher mRSSSSc patientsSerum autoantibodiesClinical phenotypeHealthy participantsScl-70 antibodyPresent multicenter studySimilar disease durationSystemic sclerosis patientsDistinct clinical phenotypesSkin gene expressionValuable clinical informationDcSSc patientsDisease durationIdentifies patientsSystemic sclerosisSclerosis patientsMulticenter studyLung diseaseSkin fibrosisSimilar prevalenceClinical dataMultivariable modeling
2021
Soluble Biomarkers for Prediction of Vascular and Gastrointestinal Disease Severity in Patients with Systemic Sclerosis
Carnaru M, Hinchcliff M. Soluble Biomarkers for Prediction of Vascular and Gastrointestinal Disease Severity in Patients with Systemic Sclerosis. Current Treatment Options In Rheumatology 2021, 7: 21-38. DOI: 10.1007/s40674-021-00171-4.Peer-Reviewed Original ResearchSystemic sclerosisSeverity biomarkersHigh-sensitivity cardiac troponin TSensitivity cardiac troponin TInternal organ involvementPlasma growth factorsNoninvasive screening toolCardiac troponin TDisease biomarkersGI involvementNT-proBNPPulmonary hypertensionCardiac involvementOrgan involvementSerum autoantibodiesEndostatin levelsEndothelial microparticlesHigh morbiditySoluble biomarkersTreatment decisionsCell adhesion moleculeNew biomarkersDisease severityTroponin TDiagnostic testing
2016
Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study
Richardson C, Agrawal R, Lee J, Almagor O, Nelson R, Varga J, Cuttica MJ, Dematte J, Chang RW, Hinchcliff ME. Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study. Seminars In Arthritis And Rheumatism 2016, 46: 109-114. PMID: 27033049, PMCID: PMC5500283, DOI: 10.1016/j.semarthrit.2016.02.004.Peer-Reviewed Original ResearchConceptsRadiographic interstitial lung diseaseSSc interstitial lung diseaseInterstitial lung diseaseSystemic sclerosisCross-sectional studyEsophageal diameterEsophageal dilatationLung diseaseProgression of ILDSSc disease subtypesPulmonary function testsRodnan skin scoreErythrocyte sedimentation rateSecondary outcome variablesBody mass indexGround-glass opacitiesProton pump inhibitorsLow lung volumesSemi-quantitative scoreRegistry patientsDisease durationLow DLCOSkin scoreMedication useSerum autoantibodies
2015
Survival in systemic sclerosis–pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry
Hinchcliff M, Khanna S, Hsu VM, Lee J, Almagor O, Chang RW, Steen V, Chung L, Investigators T. Survival in systemic sclerosis–pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry. Seminars In Arthritis And Rheumatism 2015, 45: 309-314. PMID: 26210782, PMCID: PMC4656087, DOI: 10.1016/j.semarthrit.2015.06.011.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionPulmonary Hypertension AssessmentSerum autoantibodiesRecognition of OutcomesScleroderma RegistryArterial hypertensionScl-70Hypertension assessmentAutoantibody groupsSystemic sclerosis-pulmonary arterial hypertensionSocial Security Death IndexKaplan-Meier survival estimatesSurvival estimatesIncident systemic sclerosisSSc disease durationSSc-PAH patientsRight heart catheterizationRisk of deathProportional hazards modelClinical laboratoriesElectronic medical recordsMedian followSSc-PAHAutoantibody statusHeart catheterizationMolecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures
Taroni JN, Martyanov V, Huang CC, Mahoney JM, Hirano I, Shetuni B, Yang GY, Brenner D, Jung B, Wood TA, Bhattacharyya S, Almagor O, Lee J, Sirajuddin A, Varga J, Chang RW, Whitfield ML, Hinchcliff M. Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures. Arthritis Research & Therapy 2015, 17: 194. PMID: 26220546, PMCID: PMC4518531, DOI: 10.1186/s13075-015-0695-1.Peer-Reviewed Original ResearchConceptsSystemic sclerosisEsophageal biopsiesInflammatory signatureLarge inflammatory infiltratesConsecutive SSc patientsSmooth muscle atrophyAbsence of fibrosisSmooth muscle functionProliferative gene expression signatureGene expression subsetsSmooth muscle cellsEsophageal dilatationGene expression signaturesSSc patientsEsophageal fibrosisSerum autoantibodiesInflammatory infiltrateEsophageal pathologyImmune activationAutopsy studySSc pathogenesisSSc casesMolecular subsetsGene expressionMuscle atrophy